Earnings summaries and quarterly performance for Dermata Therapeutics.
Research analysts covering Dermata Therapeutics.
Recent press releases and 8-K filings for DRMA.
Dermata Therapeutics Presents Positive Phase 3 Clinical Data for XYNGARI™
DRMA
Product Launch
New Projects/Investments
- Dermata Therapeutics, Inc. (DRMA) presented positive clinical data from its XYNGARI™ (DMT310) Phase 3 Spongilla Treatment of Acne (STAR-1) clinical trial at the European Academy of Dermatology and Venereology Congress 2025.
- The trial demonstrated statistically significant differences in Investigator Global Assessment (IGA) treatment success for XYNGARI™ compared to placebo at weeks 4, 8, and 12. At week 12, 29.4% of XYNGARI™ patients achieved IGA treatment success (2-point reduction and score of 0 or 1) versus 15.2% for placebo (p < 0.001).
- XYNGARI™ also showed statistically significant improvements in mean and percent change from baseline for both inflammatory and non-inflammatory lesion counts at weeks 4, 8, and 12 compared to placebo. For example, at week 12, the percent change from baseline in inflammatory lesion count was 59.1% for XYNGARI™ versus 45.3% for placebo (p < 0.001).
Sep 17, 2025, 10:05 AM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more